Novartis pivotal Phase III trial shows Afinitor significantly delays tumor ... MarketWatch (press release) EAST HANOVER, N.J., June 2, 2013 /PRNewswire via COMTEX/ -- Novartis today presented results from a pivotal Phase III trial of a treatment regimen including Afinitor� (everolimus) tablets in women with human epidermal growth factor receptor-2 positive ... |
